Hylan G-F 20: Review of its safety and efficacy in the management of joint pain in osteoarthritis

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders

Volumn 3, Issue , 2010, Pages 55-68

  Migliore, A ^a   Giovannangeli, F ^a   Granata, M ^b   Lagana B ^c  

^a SPietro FBF Hospital   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Hyaluronan; Hyaluronic acid; Hylan GF 20; Intra articular injection; Osteoarthritis; Review; Sodium hyaluronate; Viscosupplementation

Indexed keywords

ARTZAL; BETAMETHASONE SODIUM PHOSPHATE; HYALURONIC ACID; HYLAN GF 20; NONSTEROID ANTIINFLAMMATORY AGENT; OSTENIL; PLACEBO; SYNOCROM; SYNVISCONE; TRIAMCINOLONE HEXACETONIDE; UNCLASSIFIED DRUG;

ANALGESIA; ANKLE OSTEOARTHRITIS; ARTHRALGIA; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIP OSTEOARTHRITIS; HUMAN; INJECTION PAIN; JOINT MOBILITY; KNEE OSTEOARTHRITIS; OSTEOARTHRITIS; PSEUDOGOUT; REVIEW; SHOULDER ARTHRITIS; SWELLING; SYSTEMATIC REVIEW; TEMPOROMANDIBULAR OSTEOARTHRITIS; THUMB OSTEOARTHRITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISCOSUPPLEMENTATION; VISUAL ANALOG SCALE;

EID: 78649275625     PISSN: None     EISSN: 11795441     Source Type: Journal    
DOI: 10.1177/117954411000300001     Document Type: Review

References (65)

1. Buckwalter JA, Mankin HJ. Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instr Course Lect. 1998; 47:487-504. Review.
2. Balazs Ea. The physical properties of synovial fluid and the special role of hyaluronic acid. In: Helfet AJ, editor. Disorders of the knee, p. 61-74, 2nd edition. JB Lippincott, Philadelphia, PA, 1982.
3. Balazs EA, Denlinger JL. Sodium hyaluronate acid and joint function. J Equine Vet Sci. 1985;5:217-8.
4. Altman D. Laboratory findings in osteoarthritis. In: Osteoarthritis-Diagnosis and Medical Surgical Management, ed 2, p. 313-328, edited by R Moskowtz, D Howell, V Goldberg, J Mankin J, WB Saunders. Philadelphia, PA, 1992.
5. Balazs EA, Wason D, Huff IF, Roseman S. Hyaluronic acid in synovialfluid: I. Molecular parameters of hyaluronic acid in normal and arthritic fluids. Arthritis Rheum. 1967;10:357-76.
6. Balazs EA, Briller S, Denlinger J. Na-hyaluronate molecular size variations in equine arthritis and human arthritic synovial fluid and the effect on phagocytic cells. In: Seminars in Arthritis and Rheumatism, p. 141-143, edited by J Talbot J, Grune and Stratton. New York, 1981.
7. Simon LS. Viscosupplementation therapy with intra-articular hyaluronic acid: fact or fantasy? Osteoarthritis. 1999;252:345-57.
8. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol. 1993 Aug; Suppl 39: 3-9.
9. Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum. 2002.
10. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and the knee: 2000 update. Arthritis Rheum. 2000; 43:1905-15.
11. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2000;59: 936-44.
12. Gooberman-Hill R, Woolhead G, Mackichan F, Ayis S, Williams S, Dieppe P. Assessing chronic joint pain: lessons from a focus group study. Arthritis Rheum. 2007;57(4):666-71.
13. Berkowitz D. Proceedings of the United States. Food and Drug Administration Advisory Panel on Orthopedic and Rehabilitation Devices 11/20/1996. Farfax, VA: CASET Associates 1996.
14. Brown T, Laurent U, Manque un troisieme auteur, et al. Turnover of hyaluronan in synovial joints: elimination of labelled hyaluronan from the knee joint of the rabbit. Exp Physiol. 1991;76:125-34
15. Cubukçu D, Ardiç F, Karabulut N, Topuz O. Hylan GF. 20 efficacy on articular cartilage quality in patients with knee osteoarthritis: clinical and MRI assessment. Clin Rheumatol. 2005 Aug; 24(4): 336-341. Epub 2004 Dec 14.
16. Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: A treatment schedule study. Current Therapeutic Research. 1994;55:220-32.
17. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998 May-Jun; 20(3):410-423.
18. Chevalier X, Jerosch J, Goupille P, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010 Jan;69(1):113-9. Epub.
19. Conrozier T, Jerosch J, Beks P, et al. Prospective, multi-centre, randomized evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoralb osteoarthritis: a pilot study. Arch Orthop Trauma Surg.
20. Karlsson J, Sjögren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford). 2002 Nov;41(11):1240-8.
21. Kotevoglu N, Iyibozkurt PC, Hiz O, Toktas H, Kuran B. A prospective randomized controlled clinical trial comparing the efficacy of different molecular weight hyaluronan solutions in the treatment of knee osteoarthritis. Rheumatol Int. 2006 Feb;26(4):325-30. Epub 2005 Jun 15.
22. Jüni P, Reichenbach S, Trelle S. Swiss Viscosupplementation Trial Group. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum. 2007 Nov;56(11):3610-9.
23. Karatosun V, Unver B, Gocen Z, Sen A. Comparison of two hyaluronan drugs in patients with advanced osteoarthritis of the knee. A prospective, randomized, double-blind study with long term follow-up. Clin Exp Rheumatol. 2005 Mar-Apr;23(2):213-8.
24. Raman R, Dutta A, Day N, Sharma HK, Shaw CJ, Johnson GV. Efficacy of Hylan G-F 20 and Sodium Hyaluronate in the treatment of osteoarthritis of the knee-a prospective randomized clinical trial. Knee. 2008 Aug;15(4):318-24. Epub 2008 Apr 21.
25. Wobig M, Bach G, Beks P, et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther. 1999 Sep;21(9):1549-62.
26. Atamaz F, Kirazli Y, Akkoc Y. A comparison of two different intra-articular hyaluronan drugs and physical therapy in the management of knee osteoarthritis. Rheumatol Int. 2006 Aug; 26(10):873-8. Epub 2006 Jan 14.
27. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;19(2):CD005321.
28. Campbell J, Bellamy N, Gee T. Differences between systematic reviews/meta-analyses of hyaluronic acid/hyaluronan/hylan in osteoarthritis of the knee. Osteoarthritis Cartilage. 2007;15(12):1424-36.
29. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005321. Review.
30. Raynauld JP, Torrance GW, Band PA, et al; A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Canadian Knee OA Study Group. Osteoarthritis Cartilage. 2002 Jul;10(7):506-17.
31. Torrance GW, Raynauld JP, Walker V, et al; A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Canadian Knee OA Study Group. Osteoarthritis Cartilage. 2002 Jul;10(7):518-27.
32. Raynauld JP, Goldsmith CH, Bellamy N, et al. Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis. Osteoarthritis Cartilage. 2005 Feb;13(2):111-9.
33. Paker N, Tekdös D, Kesiktas N, Soy D. Comparison of the therapeutic efficacy of TENS versus intra-articular hyaluronic acid injection in patients with knee osteoarthritis: a prospective randomized study. Adv Ther. 2006 Mar-Apr;23(2):342-53.
34. Adams ME, Atkinson MH, Lussier AJ, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage. 1995 Dec;3(4):213-25.
35. Dickson DJ, Hosie G. A double blind, placebo-controlled comparison of hylan GF-20 against diclofenac in knee OA. J Clin Res. 2001;4:41-52.
36. Caborn D, Rush JL, Lanzer W, et al. A randomized single blind comparison of the efficacy and tolerability of Hylan GF-20 and triancinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol 2004;31:333-43.
37. Leopold SS, Redd BB, Warme WJ, Wehrle PA, Pettis PD, Shott S. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. A prospective, randomized trial. J Bone Joint Surg Am. 2003 Jul;85A(7):1197-203.
38. Conrozier T, Bertin P, Mathieu P, et al. Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: an open label multicentre, pilot study. Clin Exp Rheumatol. 2003;21(5):605-10.
39. Conrozier T, Bertin P, Bailleul F, et al. Clinical response to intra-articular injections of hylan G-F 20 in symptomatic hip osteoarthritis: the OMERACT- OARSI criteria applied to the results of a pilot study. Joint Bone Spine. 2006 Dec;73(6):705-9. Epub 2006 Aug 30.
40. Vad VB, Sakalkale D, Sculco TP, Wickiewicz TL. Role of hylan G-F 20 in treatment of osteoarthritis of the hip joint. Arch Phys Med Rehabil. 2003 Aug;84(8):1224-6.
41. Caglar-Yagci H, Unsal S, Yagci I, Dulgeroglu D, Ozel S. Safety and efficacy of ultrasound-guided intra-articular hylan G-F 20 injection in osteoarthritis of the hip: a pilot study. Rheumatol Int. 2005 Jun;25(5):341-4. Epub 2004 Mar 5.
42. Brocq O, Tran G, Breuil V, et al. Hip osteoarthritis: short term efficacy and safety of viscosupplementation by hylan G-F 20. An open label study in 22 patients. Joint Bone Spine 2002;69(4):388-91.
43. ®) in the treatment of symptomatic hip osteoarthritis. Clin Rheumatol. 2005;24: 285-9.
44. Migliore A, Tormenta S, Massafra U, et al. Intra-articular administration of hylan G-F 20 in patients with symptomatic hip osteoarthritis: tolerability and effectiveness in a large cohort study in clinical practice. Curr Med Res Opin. 2008 May;24(5):1309-16.
45. Migliore A, Tormenta S, Martin Martin LS, et al. The symptomatic effects of intra-articular administration of hylan G-F 20 on osteoarthritis of the hip: clinical data of 6 months follow-up. Clin Rheumatol. 2006;25:389-93.
46. Migliore A, Tormenta S, Massafra U, et al. 18-month observational study on efficacy of intraarticular hyaluronic acid (Hylan G-F 20) injections under ultrasound guidance in hip osteoarthritis. Reumatismo. 2006;58:39-49.
47. Migliore A, Tormenta S, Valente C, et al. Intra-articular treatment with Hylan G-F 20 under ultrasound guidance in hip osteoarthritis. Clinical results after 12 months follow-up. Reumatismo. 2005 Jan-Mar;57(1):36-43.
48. Migliore A, Tormenta S, Martin LS, et al. Safety profile of 185 ultrasoundguided intra-articular injections for treatment of rheumatic diseases of the hip. Reumatismo. 2004;56(2):104-9.Osteoarthritis.Cartilage. 13:1126-7.
49. Rennesson-Rey B, Rat AC, Chary-Valckenaere I, et al. Does joint effusion influence the clinical response to a single Hylan GF-20 injection for hip osteoarthritis? Joint Bone Spine. 2008 Mar;75(2):182-8. Epub 2007 Dec 28.
50. Tikiz C, Unlu Z, Sener A, et al. Comparison of efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis. Clin Rheumatol. 2005;24:244-50.
51. van den Bekerom MP, Rys B, Mulier M. Viscosupplementation in the hip: evaluation of hyaluronic acid formulations. Arch Orthop Trauma Surg. 2008 Mar;128(3):275-80. Epub 2007 Jun 16.
52. Luciani D, Cadossi M, Tesei F, Chiarello E, Giannini S. Viscosupplementation for grade II osteoarthritis of the ankle: a prospective study at 18 months' follow-up. Chir Organi Mov. 2008 Dec; 92(3):155-60. Epub 2008 Dec 6.
53. Witteveen AG, Giannini S, Guido G, et al. A prospective multi-centre, open study of the safety and efficacy of hylan G-F 20 (Synvisc) in patients with symptomatic ankle (talo-crural) osteoarthritis. Foot Ankle Surg. 2008; 14(3):145-52. Epub 2008 Mar 4.
54. Carpenter B, Motley T. The role of viscosupplementation in the ankle using hylan G-F 20. J Foot Ankle Surg. 2008 Sep-Oct;47(5):377-84.
55. Noël E, Hardy P, Hagena FW, et al. Efficacy and safety of Hylan G-F 20 in shoulder osteoarthritis with an intact rotator cuff. Open-label prospective multicenter study. P Joint Bone Spine. 2009 Dec;76(6):670-3.
56. Silverstein E, Leger R, Shea KP. The use of intra-articular hylan G-F 20 in the treatment of symptomatic osteoarthritis of the shoulder: a preliminary study. Am J Sports Med. 2007 Jun;35(6):979-85. Epub 2007 Mar 29.
57. Yustin D, Kryshtalskyj B, Galea A. Use of Hylan G-F 20 for viscosupplementation of the temporomandibular joint for the management of osteoarthritis: a case report. J Orofac Pain. 1995;9(4):375-9.
58. Møystad A, Mork-Knutsen BB, Bjørnland T. Injection of sodium hyaluronate compared to a corticosteroid in the treatment of patients with temporomandibular joint osteoarthritis: a CT evaluation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Feb;105(2):e53-60.
59. Yeung RW, Chow RL, Samman N, Chiu K. Short-term therapeutic outcome of intra-articular high molecular weight hyaluronic acid injection for nonreducing disc displacement of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Oct;102(4):453-61. Epub 2006 Aug 22.
60. Richie WK, Yeung James J, Xia, Nabil Samman. Image-Guided Minimally Invasive Surgical Access to the Temporomandibular Joint: A Preliminary Report. Journal of Oral and Maxillofacial Surgery. 2006 Oct;64(10): 1546-52.
61. Heyworth BE, Lee JH, Kim PD, Lipton CB, Strauch RJ, Rosenwasser MP. Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: a prospective, randomized, double-blinded clinical trial. J Hand Surg Am. 2008 Jan;33(1):40-8.
62. Figen Ayhan F, Ustün N. The evaluation of efficacy and tolerability of Hylan G-F 20 in bilateral thumb base osteoarthritis: 6 months follow-up. Clin Rheumatol. 2009 May;28(5):535-41. Epub 2009 Jan 10.
63. Mandl LA, Hotchkiss RN, Adler RS, et al. Injectable hyaluronan for the treatment of carpometacarpal osteoarthritis: open label pilot trial. Curr Med Res Opin. 2009 Sep;25(9):2103-8.
64. Andrew L, Chen Panna Desai, Edward M, Adler, Paul E. Di Cesare. Granulomatous Inflammation After Hylan G-F 20 Viscosupplementation of the Knee: A Report of Six Cases. J Bone Joint Surg Am. 2002;84:1142-7.
65. Laëtitia Michou, Chantal Job-Deslandre, Gonzague de Pinieux, André Kahan. Granulomatous synovitis after intraarticular Hylan GF-20. A report of two cases. Joint Bone Spine. 2004;71:438-440.